Tags:BioTechInformationLEDLifeManagementPlatformProductTechnologyWebsite
Nouscom is a private oncology company developing next generation immunotherapies. Nouscom’s proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines. Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures. For more information on Nouscom, please visit the company’s website at www.nouscom.com
Location: Switzerland, Basel-City, Basel
Member count: 11-50
Total raised: $62.340364M

Investors 3

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
06.11.2017Series B$48.767347...Versant Ve...5amventure...
17.05.2016Series A$13.573017...-finsmes.co...

Mentions in press and media 19

DateTitleDescriptionCategoryAuthorSource
18.05.2022Successful... VAC85135 is based on Nouscom...Success-startuptic...
22.09.2021Encouragin... NOUS-209 is Nouscom's lead c...Success-startuptic...
12.03.2021Green ligh...NOUS-PEV is a personalized vac...Developmen...-startuptic...
12.03.2021Green ligh... NOUS-PEV is a personalized v...Support-startuptic...
30.12.2020New board ... Exnaton, an ETH spinoff prov...Expansion-startuptic...
30.12.2020New board ...Exnaton, an ETH spinoff provid...People-startuptic...
28.12.2020C-suite ma...Clinerion provides its proprie...People-startuptic...
28.12.2020C-suite ma... Clinerion provides its propr...Expansion-startuptic...
13.06.2018New CEO an... Memo Therapeutics specialize...Success S...-startuptic...
07.11.2017Term Sheet...THE LITTLE PINK PILL Good mor...--fortune.co...
Show more